Replies to post #10683 on NorthWest Biotherapeutics Inc (NWBO)

[BioInfo]

I say 2.

How about this one! When is next PR going to be issued?

I say tomorrow Premarket!

[sentiment_stocks]

My guess:

4 more by May 30 including May 30.

[StockFollower]

Hi Flipper - I say 5

[RRRichmond]

I AM GOING TO SAY 3+1 . . .

Three PRs and one defensive response to "set the record straight" against a sure to come, misguided, AF attack piece.

[Doktornolittle]

Flippers New Pool:

I'm going with 7 PR's. I think 5 will be one per day, each day of next week, pre-market, with the last being the overview of the Direct data. I think that overview will be complete aggregate data for the second dose level, and spotty data for the other two dose levels, if any. Though hopefully enrollment numbers for all dose levels, for those of us who did not keep good track of what was spelled out in advance. I think the other 4 PR's will all be data on patients from the second dose level.

That leaves 2 PR's this week. Either tomorrow and Friday, or Thursday and Sunday, or Friday and Sunday. My guess is that both PR's will be more data about the Direct trial. Patient data from the second dose level.

I think they will leave ammunition for after ASCO, and that ammunition will be about the DCVax-L trial. Very near term, that might only be a Hospital Exemption for the UK.

I ran out of posts yesterday, so could not reply by the time I saw your post Flipper. Hope I made it in time for the big prize.

[longusa]

On the new pool, I think we may see only 1 more; that would be on the day of the poster or the Friday before. The reason is that I'm guessing that NW has been surprised by the negative reaction to the 1st PR. Although I personally think it was fine - it was exactly the type of PR we have been looking for since the PhI was announced as unblinded, many observers seem to automatically think the worst of NW.

So, given there is only so much data from the PhI, the one release would be the data on the poster, which hopefully gives overall summary as well as case study info, i.e., by RECIST criteria, what has been the % of response types, by dose, and especially what degree of systemic response was seen (what has been the furthest distance from an injected tumor where regression in a non-injected tumor was seen).